Mobile

Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004622-96

Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, over a 24-week period

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

After 24 weeks, to assess the effect of sitagliptin compared with placebo on the change in insulin dose in IU per day in patients with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on insulin with or without metformin, who titrate insulin glargine (Treat-to-Target). To assess the safety and tolerability of sitagliptin.

Critère d'inclusion

  • Type 2 diabetes mellitus

Liens